Moderna mRNA Cancer Vaccine Shows Promise—But There's a Catch Nobody's Talking About

What if I told you the same M I. RNA platform that made Moderna household name during the global virus that shut the world down is now being used to build a personalized cancer vaccine, custom coded from your tumor to train your immune system to hunt down what surgery can't see, particularly in melanoma. And the latest long term follow up is showing very promising results. It's reducing the risk of melanoma coming back by 49% in high risk patients after surgery. That's real data, but there's more to it than what we know. And I'm going to go through this vaccine and show you why Moderna had to partner with Merck because they lost 90% of their stock market after the sale of the global pandemic virus booster and vaccines have gone down. They're trying to rebrand themselves in cancer and many think the very turbo cancer that may have been caused by this is also why it's fueling them into the cancer space. And there's a political piece to this, there's a medical piece to this, and we're going to go through both of that and then I'm going to show you what we can do in immunotherapy because the technology that using here is the use of antigens and they're growing this and building the mirna and then putting it back into the body with 34 plus antigens from the tumor so they can try to digitally go after the tumor. And there's some issues with it. But Moderna is trying to rebrand itself into the cancer space, going beyond the global virus sales that shut the world down and trying to move into the cancer world, partnering with Keytruda, one of the top PD1 inhibitors. And there are big problems with this. Logistics, political precision, oncology. We're going to get into all of that today. I'm Doc. Dr. Dino Prado, founder of Invita Medical Centers. For the last 25 years, my team and I have helped many thousands of patients who failed some of the big cancer hospitals across the country by using an immune centric approach that's based on deep precision and targeting. We get out of guesswork and we get out of dogma and we get into data and that's what's helped us help so many of our patients. And I'm going to share with you today this brand new Mirna Moderna vaccine for cancer, how it's exploding and what's happening politically. And we're going to also go into some other immunotherapy techniques that in my clinical opinion Actually may work better and give our body's real response instead of a synthetic one. This is remember, always for educational purposes and make sure you're working with a doctor before you change anything. So let's get started. So who's Moderna? Many of us have heard of the Mirena vaccine. It was founded in 2010 and their stock exploded. Their valuation was high. But then afterwards we saw the sale of these boosters go down and their market share in Stock dropping by 90%. And even in 2025, they had a decrease in 45% in Reven. So this company is trying to rebrand itself and it's using this MRNA technology to move into cancer. The first political problem is a lot of people have a hard time trusting this data based on what happened during the global pandemic. So based on that, they're rebranding themselves, partnering with Merck. Merck's got an established name. They're huge in the oncology world. Keytruda is not a small drug. On its own, it's described as one of the world's top selling immunotherapy drugs. So you can see why Moderna wanted to partner with them, because it's gonna cost them a lot to re themselves in cancer. So they want to stimulate the immune system with the M rna, which I'll go over here in a minute. And at the same time then use Keytruda or PD1 inhibitors to take the break off and get some really good results for patients. But there are some issues that we're going to cover as well. So this is for high risk, stage three four melanoma patients after surgical removal. So at about five years, Moderna and Merck reported that the combo continued to reduce risk of reoccurrence of death by 49%. That's huge. And earlier studies reported 62% reduction in the risk of disc metastasis or spread. And that's why this is being called a breakthrough. To me it sounds like a strong rebrand and we always have to be very careful. Pharmaceutical companies are masters at skewing data in their favor. Here's how it works. The sequence of the tumor. So they took a tumor's DNA and it uses 34 patient specific neoantigens. Then it basically wraps it in a fat molecule, injects it into your body and it cloaks the uridine. So the uridine part of the rna, it cloaks it. It uses a methyl group on there, it causes a pseudourid so that your body's immune system doesn't attack it. And so it can live in the body and stimulate your immune system to go after this cancer. Now, keytruda comes in as a piggyback because it's a PD1 inhibitor helping to stimulate the T cells. And the combination of this, because it's already used in melanoma, it is an opportunity to bring the drug to market fairly quickly. Now, here's the piece you have to see. There's several shortcomings to this from an immunological perspective. First of all, safety. We're waking up the immune system and we don't want to overshoot it. So remember that cancers have heterogenicity. They have a lot of changes within the same tumor that make it different. So if we build this outside the body, it takes like 30 days to make this vaccine and return it. The cancer could have mutated beyond that. That's one issue that can happen because some of the fast growing cancers, particularly in late stage, every three, four, six weeks, they can mutate, making these antigens less effective. That's maybe why it's not working on everybody. Secondly, it can cause an autoimmune reaction in the body. So doctors have to watch these patients carefully because now you're stimulating this mirna to integrate into your own genome. So this could cause potential autoimmunity. It can cause a cytokine storm where essentially you get this massive release of inflammation throughout the body from the tumor die off. And so the patients need to be monitored. But what I want you to understand is that we're moving into a time in oncology where they're starting to custom engineer drugs based on getting some tumor information, making some neoantigens, 34 of them. They're cloaking the RNA MRNA so that it actually doesn't get attacked by your body's own immune system. Your immune system's intelligent. If it sees something foreign, it's going to take it out. They cloak it so this actually makes it to the nucleus with lipids and stimulates the immune system to fight the cancer. All of that sounds great, but there's pieces that are missing. If people have tumors that are cold and not visible, it's not going to work that well because cold tumors have environments around themselves, gangs that block your immune system from fighting it. And so it can't penetrate the tumor in the way you want. So you have to be careful with the tumor microenvironment. That isn't really addressed here. Other important parts are manufacturing bottlenecks and changing the branding. Because after what happened in the world with the global pandemic virus. Everybody's really worried about M and for rightful reasons a lot of integrative people believe that they, you know, contributed to turbo cancers and now they're going to make money solving the problem. So there's a concern there. And because they're burning through so much cash, moderna billions to make these studies move, they are moving outside the United States because to push these phase three studies, they're moving away from the Kennedy administration who's more working on safety than on efficacy. Meaning when you do these fast track studies, you're only looking at response rates. So the tumor might shrink by 30, 40% and then we don't know how it's going to respond in long term. They're showing good long term data but they're moving the studies out of the US like UK and Europe, so they can fast track these drugs and then bring them back into the US and so there's concerns about this. But what I want to do is get into the science of the immunotherapy. If the disease is moving faster than the drug, it's not going to work. If we're not dealing with the tumor microenvironment, it isn't going to work. And so those are some of the bottlenecks that we have. If we have an overstimulation of the immune system, maybe it's not going to work the way we want. And we're not getting all the details of the tumor, we're just getting these 34 manufactured neoantigens and other stimulators. It's not the same thing. Everything that's actually in the tumor and the way your body normally builds immunotherapy is it tries to get all the information of the tumor gets passed on to your dendritic cells, T cells, natural killer cells, and then they go after the tumor. So let me give you my understanding from my clinical experience working 25 years in the area of developing immunotherapy, where I see shortcomings and here's some solutions to overcome that. So I'm going to compare this directly to direct to tumor chemo immunoprecision injection, where after deep mapping DNA, RNA transcriptomics, immune spatial biolo biology and profiling. So now you have all the information of the tumor, you build the right medicines on and off labels, stimulate the tumor itself to release the information in the body and the way it naturally normally would so that your immune system can pick up the snapshots and information in the Moderna vaccine. You have. Let's say 34 neoantigens. So think of it as like you have these detectives, your dendritic cells and they're giving it 34 different pictures, maybe the fingerprint, the mug shot, all of the different components from the crime scene, but that's all you have. And then that's being manufactured in 30 and re entered into the body. And the goal is that that's trying to deal with the heterogeneicity, meaning the variation within the cancer that can occur. You've heard me say this before. You can have two people with the same types of cancer in stage and have totally different markers. Well, you can have the same cancer tumor that has different markers within the same body. That's why building custom immunotherapy is so important in the difference with CPI is when you open up the tumor and stimulate the immune system at the tumor. With directed tumor interventional radiology, oncology, you're releasing all the information, you're releasing the antig, the tumor fragments, the damage, associated molecular patterns and all that information is being custom built with the patient. And we don't have this concern of autoimmunity, we don't have this concern of longer term reactions that we're not familiar with that can happen when we mess with RNA and use it as a vaccine. Now if you're an end stage melanoma patient and this is a clinical trial option for you, and it's the difference between living and dying that's very different than treating healthy people with global pandemic vaccines that may not be of any benefit to them. So I can see that. But at the same time we have a way of stimulating the body's tumor directly using non invasive or what I like to call invisible surgery, a catheter the size of a hair delivering the custom developed immunotherapy and transcriptomics biomarker targets directly to the tumor so we can shut down its growth pathway, get the T cells to get stimulated and now give a less of a chance of the tumor evading because it's being built right there at the tumor at that moment. It's not 30 days later where we taking out a piece of information and then building it outside the body, returning it with a shot and a lipid molecule, try to get it cloaked into the cell. That's what the moderna vaccine does with the hope of shutting down the cancer versus going directly to the tumor, hitting the tumor, letting the tumor open up, stimulating the immune system and more importantly stopping the immune evasion. Because if you look at the Tumor from a spatial biology perspective, you have all these cloaking mechanisms that will stop your immune system from attacking the tumor. When you have these multi omics or all this DNA, rna, all the stuff I've just been talking about immune spatial biology and you know the tumor microenvironment, you can build a sequence right into the CPI direct to tumor respons so that you can get the antigens exposed, tumor fragments exposed, the damage associated molecular patterns exposed. And now you have the advantage. Now they're starting with melanoma. And the reason is, is because melanoma is already at immunotherapy centric cancer, it's going to be more likely to respond and it's already really approved with PD1 inhibitors. So there's a partnership there with Merck. Merck has the money and the power to push this Moderna vaccine worldwide. But we're entering into a new chapter of healthcare. You're starting to see now the tumor being taken out, antigens being made synthetically digitally re entered into the body like a VACC vaccine to go after the tumor and hoping that it kills the cancer. And I think it's you know, very interesting technology, but I do think there's better ways going direct to tumor because we're using the body's own natural mechanism. The only difference is you can't patent that one right. The Moderna is going to be a massive multi billion dollar drug with Merck. And right now if you looked at it, Moderna stock is probably in the 40s and at one time it was like $480 a share. So you can see they're trying to rebrand themselves, work with Merck and get back into the market with this new V940 Mirna vaccine. Can run deeper profiling though. So if we have the information of the tumor in the technology of cpi, chemo immunoprecision injection, we can go further. We can look at all the DNA, all the rna, all the immune system information and spatial biology and then build a treatment that's not just for melanoma, but for many. Or what we like to use it on in our clinical experience is really all tumors, especially those that are cold and need to be hot. Melanoma cancers are naturally hot tumors, meaning they're already immune centric, they're more prone to the immune system working. But a lot of cancers, it could be breast, colon, prostate, pancreatitis and many others have cold tumors. And so those cold tumors need to be turned on. And so this technique with sippy allows us to Address that tumor microenvironment, which is the key, without creating a potential systemic autoimmune disease and monitoring a cytokine storm that can occur and those types of things which are a concern with a vaccine like this. So this is really powerful information. And you know, people are worried about the politics of this being a circular economy. They developed the global pandemic treatment. Many thought that was related to turbo cancers or other complications, right. Cardiac and others. And now they're developing a solution and going after the market share again. So they were a one hit wonder in the global pandemic world, Moderna. Now they're partnering with Merck to move that towards oncology. And there might be something there. But I want to educate you so you understand the potential dangers and understanding immunotherapy. That I think we can do even better immunotherapy if we build it custom for each patient using true precision oncology. This is an idea that, yes, it's precision because we're taking it out of the body and we're building it and returning it. But I'm talking about precision oncology at a much deeper level that can be done at the tumor and directly delivered for each patient. The only difference is you can't mass produce that. So I hope you understand the potential excitement with new treatments like this, but also some of the limitations and how we might be able to do even better with custom immunotherapy. Now I know more than 90% of you watching this aren't subscribed. It helps us to spread the word of precision oncology so people don't get trapped in the one size fits all model because of the YouTube algorithms. You subscribe and share and suddenly the rest of the world gets to see the information. And we help doctors and patients and others open their mind. Targeted care. I hope you found this information helpful and may the Lord bless you on your journey to healing.